3.11.2023 | Forbes
By Steve Brozak
Six months ago, I wrote in Forbes how the Fed’s Inflation fight would harm Biotech. With the FDIC takeover of Silicon Valley Bank (SVB) using the receiver, Deposit Insurance National Bank of Santa Clara the judgment has proven to be correct. And what could happen next may be even more disruptive. From its high two years ago, the XBI biotech index has lost 50% of its value and far from being at a bottom, SVB’s demise poses an additional and un-quantifiable life-sciences systemic risk and there isn’t anything the FDIC will be able to do about it.
So, what are the 5 critical questions and answers about SVB and Biotech?
To read the entire article on Forbes, please click here…